Stephanie Mompoint, APRN

Subcutaneous daratumumab offers shorter clinic visits and high tolerability for patients with multiple myeloma, says Stephanie Mompoint, APRN.

Education before subcutaneous daratumumab administration can both reassure patients and reduce the occurrence of adverse events, according to Stephanie Mompoint, APRN.